Einecs 302-787-9 | 94134-20-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Einecs 302-787-9
• 英文别名: (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol;4-oxopentanoic acid
• CAS: 94134-20-0
• 化学式: C15H23NO4
• 分子量: 281.35
• InChiKey: GOIRTRRWMFGSBU-GNAZCLTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT
  申请人：Institut Gustave Roussy

  公开号：EP2561088A1

  公开（公告）日：2013-02-27
• Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
  申请人：Institut Gustave Roussy

  公开号：EP2806034B1

  公开（公告）日：2017-06-28
• US8865653B2
  申请人：——

  公开号：US8865653B2

  公开（公告）日：2014-10-21
• US8828944B2
  申请人：——

  公开号：US8828944B2

  公开（公告）日：2014-09-09
• [EN] COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT<br/>[FR] COMPOSÉS ET UTILISATIONS DE CEUX-CI POUR INDUIRE LA MORT D'UNE CELLULE CANCÉREUSE IMMUNOGÈNE CHEZ UN SUJET
  申请人：ROUSSY INST GUSTAVE

  公开号：WO2011131246A1

  公开（公告）日：2011-10-27

  The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof.